2008 News Releases

Corporate

8.6.08		The Quigley Corporation Names Gerard M. Gleeson To Succeed Retiring George J. Longo As Chief Financial Officer and Director
7.7.08		The Quigley Corporation Joins the Russell Microcap Index
3.3.08		The Quigley Corporation Announces Sale of Its Health and Wellness Segment

Financial

7.31.08		The Quigley Corporation Reports Second Quarter 2008 Results
4.24.08		The Quigley Corporation Reports First Quarter 2008 Results
3.3.08		The Quigley Corporation Reports Foruth Quarter & 2007 Annual Results

2007 News Releases

Corporate

12.6.07		The Quigley Corporation to Present at NYSSA Biotech/Specialty Pharma Conference
5.22.07		The Quigley Corporation Launches Two Cold-EEZE Brand Extensions Including First in Marketplace Organic Cough and Sore Throat Drop
5.1.07		The Quigley Corporation Retains CRT Capital Group LLC As Financial Advisor and Investment Banker

Financial

10.25.07		The Quigley Corporation Reports Third Quarter Results
7.26.07		The Quigley Corporation Reports Second Quarter Results
4.26.07		The Quigley Corporation Reports First Quarter Results
2.27.07		The Quigley Corporation Reports Fourth Quarter and Annual Results

2006 News Releases

Quigley Pharma

8.28.06		Quigley Pharma press releases are now on the Quigley Pharma website

Corporate

7.12.06		The Quigley Corporation Test Markets PainGoes® a New OTC Pain Relieving Spray
7.12.06		Baseball Hall of Fame Relief Pitcher Rollie Fingers Featured in New Vlog
2.10.06		The Quigley Corporation Partners with Universal Pictures to Launch Curious George™ Promotion for its Cold-Eeze® Brand

Financial

10.26.06		The Quigley Corporation Reports Third Quarter Results
7.27.06		The Quigley Corporation Reports Second Quarter Results
4.26.06		The Quigley Corporation Reports First Quarter Results
2.23.06		Quigley Increases Revenues to $53.7 Million; Net Income to $3.2 Million for Fiscal Year;

2005 News Releases

Quigley Pharma

12.9.05		Quigley Pharma Compound QR-442 Shown to Delay Onset of Disease and Lower Disease Severity in Animal Multiple Sclerosis Model
12.8.05		Quigley Pharma's Compound QR-336 Shown to Protect Mice From Lethal Exposure to Ionizing Radiation
12.6.05		Quigley Pharma Issued An Investigational New Animal Drug (INAD) Number By The FDA To Study Its Anti-Viral Compound For Avian Flu In Pigs
12.1.05		Quigley Pharma's Compound QR-441 Shown to Increase Protectivity Against H5N1 Avian Flu When Impregnated into Commercially Available Respiratory Face Masks
11.9.05		The FDA Issues Four Additional Investigational New Animal Drug (INAD) Numbers To Quigley Pharma To Study Its Anti-Viral Compound QR-441A On Companion Animals (Pets)
11.8.05		Quigley Pharma is Issued Three Investigational New Animal Drug (INAD) Numbers by the FDA To Study Its Anti-Viral Compound On Avian Flu
11.3.05		The Quigley Corporation Retains Brocair Partners LLC to Provide Strategic Option Evaluations for Quigley Pharma's QR-340 Scar Formula
10.26.05		Quigley Pharma's QR-442 Compound Shows Positive Effect on Multiple Sclerosis Mouse Model
10.18.05		Pre-Clinical Toxicity Studies Show Quigley Pharma's Diabetic Neuropathy Formulation QR-333 is Safe for Topical Application
9.7.05		Journal of Diabetes and Its Complications Publishes Favorable Study Addressing Quigley Pharma's Diabetic Neuropathy Formulation QR-333
8.1.05		The Quigley Corporation Announces Positive In-Vitro Study Results of its QR440 Compound Support Conclusions of Previous Animal Study Findings
6.28.05		The Quigley Corporation Announces Results of Animal Model Inflammation Studies of Its QR440 Botanical, Anti-Inflammatory Compound
4.18.05		Quigley Pharma's Formula for Improving Scar Appearance Shown to be Effective in Double-Blind Study
1.24.05		Quigley Pharma Announces Research and Development Update

Corporate

11.3.05		The Quigley Corporation Retains Brocair Partners LLC to Provide Strategic Option Evaluations for Quigley Pharma's QR-340 Scar Formula
11.1.05		Nationwide Public Awareness Campaign to Educate Seniors About Proper Use of OTC Medicines Launched by National Council on the Aging and The Quigley Corporation
10.19.05		Independent Double-Blind Placebo-Controlled Study Demonstrates Safety of Cold-Eeze in a Geriatric Population
8.24.05		The Quigley Corporation Selects Award-Winning Merkley + Partners as Avertising Agency of Record

Financial

11.14.05		Quigley Amends Quarter Results
10.27.05		Quigley Reports Third Quarter Results
7.28.05		Quigley Reports Second Quarter Results
4.28.05		Quigley Reports First Quarter Results
2.24.05		Quigley Increases Revenues for the Fourth Quarter and Fiscal Year

2004 News Releases

Quigley Pharma

12.20.04		Quigley Pharma Appoints Two New Members to its Scientific Advisory Board
10.12.04		Quigley Receives Patent Approval for Arthritis Treatment
7.12.04		The Quigley Corporation Receives U.S. Patent for Its Topical Treatment for Radiation Dermatitis
5.10.04		Quigley Pharma's QR-435 Continues to Show Pre-Clinical Results; Latest Study Determines Significant Influenza A Therapeutic Effect in Animals
4.5.04		The Quigley Corporation's Proprietary Formula QR-336 Protects Mice in a Lethal-Dose Radiation Study
3.29.04		Quigley Pharma Conducts Pre-IND Meeting with the FDA on its Diabetic Peripheral Neuropathy Formulation
3.3.04		Professor Paul Valensi to Present Research on Quigley's QR-333 at the Diabetes 2004 Conference in Nice, France
2.17.04		Retroscreen Virology to Present Research on Quigley's QR-435 at the VI International Symposium on Respiratory Viral Infections
1.26.04		Quigley Provides Further Updates on Compound QR-435
1.20.04		Quigley Provides Updates on Quigley Pharma's Business and Research Activities

Corporate

11.5.04		Officials for The Quigley Corporation Respond to News Reports about Nasal Spray Lawsuit
11.3.04		The Quigley Corporation Announces Launch of BEVERLY SASSOON Product Line by its InnerLight Subsidiary
10.5.04		Quigley Completes Purchase of Manufacturing Assets of JOEL
8.20.04		Quigley to Purchase Manufacturing Assets of JOEL
7.30.04		The Quigley Corporation Declares a Stock Dividend of Suncoast Naturals, Inc. Common Stock Acquired In Its Sale of Caribbean Pacific Natural Products Subsidiary
7.16.04		The Quigley Corporation Engages Amper, Politziner & Mattia, P.C. as Independent Accountants
6.3.04		The Quigley Corporation Provides an Update of its Proposed Stock Dividend of Shares of Common Stock of Suncoast Naturals, Inc.
5.3.04		Quigley Announces New Board Member

Financial

10.28.04		Quigley Reports Third Quarter Results
7.30.04		Quigley Reports Second Quarter Results
4.29.04		Quigley Reports First Quarter Results and Provides Updates on Pharmaceutical Segment
2.26.04		Quigley Reports 43.8% Increase in Revenue for Forth Quarter - Achieves Profitability in 2003 while investing $3.4 Million in R&D

2003 News Releases

Quigley Pharma

12.08.03		Quigley's Compound For Influenza Tests Positive in Preliminary in vitro SARS Virus Study
11.06.03		Quigley's QR-435 Test Compound 100% Effective in Animal Prophylaxis Experiment
9.24.03		The Quigley Corporation to Begin Preliminary Testing of Quigley Pharma's Formulation for SARS
9.3.03		The Quigley Corporation Intends to File for Permission to Study Its Patent Pending Potential Treatment for Psoriasis and Other Skin Disorders
7.29.03		The Quigley Corporation Receives US Patents for its New Formulation Being Tested to Relieve Sialorrhea
6.12.03		The Quigley Corporation Receives U.S. Patent For Its Topical Pain Relief Treatment of Diabetic Neuropathy
4.8.03		The Quigley Corporation Announces Positive Results of Quigley Pharma's Proof of Concept Study of its Diabetic Peripheral Neuropathy Formula
2.11.03		The Quigley Corporation's Plans to Submit IND for New Formulation
1.14.03		The Quigley Corporation's New Formulation Found to Reduce Influenza Impact in New Study

Corporate

5.12.03		Second Heritage School Study Confirms COLD-EEZE® Lozenges As Effective Common Cold Treatment in Adolescent Population
4.10.03		The Quigley Corporation Introduces Kidz-EezeTM Lollipop to Soothe Sore Throats - First Product in Quigley Line Targeted Specifically To Kids
2.25.03		The Quigley Corporation Introduces COLD-EEZE Nasal Spray; Contains Zinc Gluconate To Treat Common Cold and Aloe Vera to Soothe Nasal Passages
2.19.03		The Quigley Corporation's Annouces Stock Dividend of Stock Acquired in Sale of Caribbean Pacific Subsidiary

Financial

10.28.03		The Quigley Corporation Reports 26.5% Increase in Revenue for the Third Quarter
7.24.03		The Quigley Corporation Reports 38.6% Increase in Revenue for the Second Quarter
4.29.03		The Quigley Corporation Reports First Quarter Results, Increases Revenues by 60%
3.19.03		The Quigley Corporation Revenue For The Year Up 29%

2002 News Releases

Corporate

12.12.02		The Quigley Corporation Convenes Scientific Advisory Board for Quigley Pharma
7.23.02		Update: The Quigley Corporation Urges Investigation of Unattributed "Research"
7.22.02		The Quigley Corporation Urges Investigation of Unattributed "Research"
6.5.02		Forrester Invests $3.2 Million in The Quigley Corporation Exercises 500,000 Warrants

Financial

10.24.02		The Quigley Corporation Third Quarter Revenue Up 17%
7.25.02		The Quigley Corporation Second Quarter Revenue Up 25%
4.10.02		The Quigley Corporation Schedules Investor Conference
2.19.02		The Quigley Corporation Reports Net Income of $216,000 In 2001 vs. $5.2 Million Loss in 2000

Quigley Pharma

10.1.02		The Quigley Corporation's Independently Audited In-Vitro Studies Reveal New Formulation Kills Influenza Virus Strains
9.3.02		The Quigley Corporation Files Foreign Patent Application For Diabetic Neuropathy Treatment
8.7.02		The Quigley Corporation's New Formulation Found to Kill Infectious Herpes Virus
7.24.02		The Quigley Corporation Updates Phase II Proof Of Concept Study For Diabetic Neuropathy Formulation
7.16.02		The Quigley Corporation Targets ALS Medication for Over-the-Counter Distribution
7.9.02		The Quigley Corporation Announces Phase II Clinical Study on QR-334 Formulation to Relieve Sialorrhea Symptoms
5.2.02		New Quigley Pharma and Cold-Eeze Patent Applications Highlighted at The Quigley Corporation Annual Meeting
4.11.02		The Quigley Corporation Initiates Proof of Concept Study on Diabetic Neuropathy Formulation

COLD-EEZE®

11.21.02		Independent Study Finds That Daily Dose of COLD-EEZE Cuts the Chances of Catching a Cold By More Than 50%
10.8.02		U.S. Centers for Disease Control Approves Partnership Agreement With The Quigley Corporation
4.16.02		NEW COLD-EEZE® ADOLESCENT STUDY: Effective in Preventing Colds; Reduces Use of Antibiotics & Reaffirms That COLD-EEZE® Reduces Cold Symptoms By 4 Days
4.17.02		The Quigley Corporation Announces New Cold-Eeze Patent Application; Outlines Potential Process and Timetable for Approval of Topical Diabetic Neuropathy Treatment
3.25.02		New Study Confirms Cold-Eeze® Reduces Antibiotic Use

2001 News Releases

Corporate

6.8.01		The Quigley Corporation, Maker of Cold-Eeze®, Wins Settlement in Patent Infringement Suit Against Gum Tech
4.26.01		The Quigley Corporation Names Joseph C. Casey Vice President, Sales & Marketing

Financial

7.26.01		The Quigley Corporation Reports Second Quarter Results, Cuts Loss by 59%
4.26.01		The Quigley Corporation Reports First Quarter Results, Cuts Loss by 90%

Quigley Pharma

11.14.01		The Quigley Corporation Assigned Patent Application For Radiation Dermatitis Treatment
9.25.01		The Quigley Corporation Files Patent for Lozenge that Relieves Symptom of Lou Gehrig's Disease (ALS)
6.26.01		The Quigley Corporation Names Richard A. Rosenbloom, M.D., Ph.D., Executive Vice President of Quigley Pharma Inc.
1.30.01		The Quigley Corporation Announces Ethical Pharmaceutical Division
1.10.01		The Quigley Corporation Files Patent for Topical Pain Relief Treatment for Diabetics

COLD-EEZE®

10.02.01		The Quigley Corporation Announces COLD-EEZE® Marketing Initiatives
7.12.01		New Study Confirms Sugar-Free Cold-Eeze Safe for Diabetic Patients; Results Published in American Journal of Therapeutics